Cancer genetic & biomarker testing in Istanbul, Turkey
Biomarker testing looks for genes, proteins and other molecules in a tumour sample or in blood to help choose treatment. It is the gatefor targeted therapy and immunotherapy — without a matching biomarker such as HER2, EGFR, PD-L1 or an MSI-high result, those drugs will not help. Istanbul labs run single-gene tests, comprehensive next-generation sequencing panels and liquid biopsy, often at JCI-accredited, state-authorized centers and below Western-European prices. Because the test matters more than where treatment happens, the honest first step is confirming the right biomarker is already on your reports. Every price we show is an illustrative placeholder until verified partner quotes exist — and you pay the hospital or lab directly, never us. Start with a free 72-hour review.
What cancer biomarker testing is
The U.S. National Cancer Institute describes biomarker testing for cancer treatment as a way to look for genes, proteins and other molecules — called biomarkersor tumour markers — in a sample of tumour tissue or in blood. Biomarkers can be made by the cancer itself or by the body in response to it, and they give a molecular picture of a specific tumour that a scan or a standard biopsy alone cannot. This is a diagnostic step, not a cancer in its own right.
The reason it matters is simple: per the NCI, biomarker testing helps match a patient to the treatments most likely to work — it is what tells the team whether a targeted therapy or an immunotherapy drug has a target to hit. Without a matching biomarker, those drugs are unlikely to help, so confirming the correct test has been done on your reports can change the plan more than the choice of hospital. Browse the wider cancer types hub for the diagnoses these tests support.
What gets tested and why
The main kinds of biomarker testing the NCI describes, and an honest note on each:
- Single-biomarker tests. A test for one specific change that unlocks one specific drug — for example HER2 in breast and stomach cancer, EGFR or ALK in lung cancer, BRAF in melanoma, or KRAS in colorectal cancer. A positive result opens a matching targeted therapy; a negative result means that particular drug is not the answer.
- Immunotherapy biomarkers. PD-L1 expression, MSI-high or mismatch-repair-deficient status, and tumour mutational burden help predict whether checkpoint-inhibitor immunotherapy is likely to work. They do not guarantee a response, but they are how the team decides whether immunotherapy is worth trying at all.
- Inherited (germline) testing. Tests such as BRCA1/2 look for changes you were born with rather than ones the tumour acquired. Results can affect treatment choices, guide screening, and flag risk for blood relatives — which is why genetic counseling usually goes with them.
- NGS panels and liquid biopsy. Comprehensive next-generation sequencing reads many genes from one sample at once; a liquid biopsy is a blood test that detects tumour DNA when tissue is hard to obtain or when the cancer needs to be watched over time. Both are broader and priced above a single-gene test.
See how the drugs these tests unlock actually work on the targeted therapy and immunotherapy pages, or the wider treatments & technology hub.
What it costs
There is no single biomarker-testing price, because the cost depends on which test is done— a single-gene test such as HER2 or EGFR is far cheaper than a comprehensive next-generation sequencing panel that reads hundreds of genes at once, and a liquid biopsy is priced differently again. Testing is also usually one line item inside a larger treatment plan, not a standalone purchase. Every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital and lab quotes, and each is itemized so you can hold a real quote up against it line by line. See the Turkey Oncology Price Index or the full cancer treatment cost in Turkey breakdown, and run any written quote through the quote check first.
The hospital, verified
We don’t show a wall of smiling pathologists or a “ranked” list of labs — those are the easiest things to fabricate. Instead, you’re matched to one state-authorized Istanbul partner hospital whose molecular pathology and medical oncology subspecialty fits your diagnosis, and you can verify its authorization against the Republic of Turkey Ministry of Health’s own records and its JCI accreditation in JCI’s public directory before you commit. Named specialist profiles appear only when a verified, consented physician is behind the name. See the full guide to cancer hospitals in Istanbul and how to check one yourself.
Where this fits
Biomarker testing is the diagnostic step that sits in front of targeted therapy — the overview it belongs to — within the broader cancer treatment in Istanbul pillar. If you want your own reports read first, a free second opinion organizes and verifies your pathology and imaging — including whether the key biomarker has already been tested — into a plain-language case file in your language before you decide whether to travel. You can also check the citable facts behind everything on this page.
Related treatments & diagnostics
Check everything here — us included
Common questions
Can I get cancer genetic and biomarker testing in Turkey?
Yes. Istanbul hospitals and their molecular pathology labs run the biomarker testing the U.S. National Cancer Institute describes — single-biomarker tests such as HER2, EGFR, ALK, BRAF and KRAS, immunotherapy biomarkers such as PD-L1 and MSI status, inherited BRCA1/2 testing, and comprehensive next-generation sequencing panels. Some tissue can also be sent to specialist reference labs abroad. The honest point is that the test matters more than the postcode: a case review of your existing pathology will flag whether the biomarker your treatment depends on has already been tested, so you do not repeat or miss it before you decide anything.
What biomarkers are commonly tested — HER2, EGFR, PD-L1, BRCA?
It depends entirely on the cancer, but per the NCI common ones include HER2 in breast and stomach cancer, EGFR and ALK in lung cancer, BRAF in melanoma, and KRAS in colorectal cancer — each can unlock a specific targeted drug. Separately, PD-L1 expression, MSI-high or mismatch-repair-deficient status, and tumour mutational burden help predict whether checkpoint-inhibitor immunotherapy is likely to work. Inherited BRCA1/2 testing affects both treatment options and family risk. Which of these applies to you is decided by your diagnosis and reports, not a template — this is general information, not a treatment recommendation.
What is a liquid biopsy?
A liquid biopsy is a blood test that looks for fragments of tumour DNA and other cancer molecules circulating in the bloodstream, rather than taking a piece of the tumour itself. The NCI describes it as a way to detect biomarkers when a tissue sample is hard to obtain, and as a tool that can be repeated over time to watch how a cancer is responding. It does not replace a tissue biopsy in every situation, and results still have to be interpreted by the treating team. Whether it fits your case is a clinical decision, and a case review will note what your reports already establish.
How much does biomarker testing cost in Istanbul?
There is no single figure, because the cost depends on which test is done — a single-gene test such as HER2 or EGFR is far cheaper than a comprehensive next-generation sequencing panel that reads hundreds of genes at once, and a liquid biopsy is priced differently again. Istanbul typically runs below Western-European prices for the same assay, but every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital and lab quotes, itemized so you can check a real written quote line by line. You pay the hospital or lab directly, never us. See the Turkey Oncology Price Index for current ranges.
Start with a free 72-hour case review
Send your pathology and imaging. Get a verified case file in your language — free, confidential, no obligation.
This page is general information, not medical advice. Medical facts are grounded in the U.S. National Cancer Institute; prices shown are illustrative placeholders pending verified partner-hospital quotes, not offers. Every cancer case is individual; assessments are based on the reports you provide and do not replace in-person examination.